Clinical Trials Sponsored by Spectrum Pharmaceuticals, Inc

Total 4958 results

Spectrum Pharmaceuticals, Inc

Suspended

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE)

NSCLC

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Breast Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia (BPH) | Lower Urinary Tract Symptoms (LUTS)

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
Spectrum Pharmaceuticals, Inc

Terminated

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer (NSCLC)

United States
Spectrum Pharmaceuticals, Inc

Completed

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Prostate Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

Bladder Cancer

United States
Spectrum Pharmaceuticals, Inc

Completed

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Lung Cancer

United States, Canada
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Non-small Cell Lung Cancer

United States, Czechia, India, Brazil, Argentina, Hungary
Spectrum Pharmaceuticals, Inc

Completed

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Metastatic Malignant Uveal Melanoma

United States
Spectrum Pharmaceuticals, Inc

Completed

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Bladder Cancer

Canada, United States, Poland
Spectrum Pharmaceuticals, Inc

Completed

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer (ENRICH)

Breast Cancer | Metastases

United States, Canada, France, Spain, United Kingdom, Austria, Argentina, Brazil, Chile, Croatia, Greece, Hungary, Italy, Lithuania, Peru
Spectrum Pharmaceuticals, Inc

Recruiting

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Breast Cancer | Neutropenia

United States
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

United States, Canada, Netherlands, Belgium, Israel, Spain, France, Italy
Spectrum Pharmaceuticals, Inc

Completed

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Neutropenia

Australia, Poland, United States, Hungary, Israel, Georgia
Spectrum Pharmaceuticals, Inc

Completed

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) (ADVANCE)

Breast Cancer | Neutropenia

United States, Canada, Korea, Republic of
Spectrum Pharmaceuticals, Inc

Completed

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Breast Cancer | Neutropenia

United States, Canada, India, Hungary, Korea, Republic of, Poland
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Bladder Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Glioblastoma Multiforme

United States, India
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Spectrum Pharmaceuticals, Inc

Completed

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Healthy

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Solid Tumor

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Breast Cancer

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Healthy

United States
Spectrum Pharmaceuticals, Inc

Completed

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

Small Cell Lung Cancer | Ovarian Cancer | Solid Tumors

United States
Spectrum Pharmaceuticals, Inc

Completed

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

EGFR Inhibitor-associated Rash

United States, Canada
Spectrum Pharmaceuticals, Inc

Completed

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Non-Hodgkins Lymphoma | Tumors | Hodgkins Disease

United States, Canada
Spectrum Pharmaceuticals, Inc

Completed

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb (SPI-014)

Safety | Phosphate Binding Capacity

United States
Spectrum Pharmaceuticals, Inc

Completed

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

Carcinoma

United States
Spectrum Pharmaceuticals, Inc

Terminated

Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Advanced Solid Tumors

United States
Spectrum Pharmaceuticals, Inc

Withdrawn

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Belgium, Israel
Spectrum Pharmaceuticals, Inc

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Lymphoma | Solid Tumors

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Breast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome Multiforme

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Breast Cancer | NSCLC

United States
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Spectrum Pharmaceuticals, Inc

Terminated

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Peripheral T-cell Lymphoma

Belgium, Spain, United States, Australia, France, Israel, Canada, United Kingdom, New Zealand, Italy, Ireland, Poland, Puerto Rico
Spectrum Pharmaceuticals, Inc

Completed

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Benign Prostatic Hypertrophy

United States
Spectrum Pharmaceuticals, Inc

Terminated

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Biliary Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Follicular Lymphoma

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Acute Lymphoblastic Leukemia (ALL)

United States
Spectrum Pharmaceuticals, Inc

Completed

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Metastatic Cancer

France, United States, Canada, Belgium, Italy, Australia, United Kingdom, Germany, Hungary
Spectrum Pharmaceuticals, Inc

Completed

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

Bladder Cancer

United States
Spectrum Pharmaceuticals, Inc

Completed

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Breast Cancer | Pharmacokinetics

United States
Spectrum Pharmaceuticals, Inc

Withdrawn

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States, Russian Federation
Spectrum Pharmaceuticals, Inc

Withdrawn

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

Leukemia

United States
Spectrum Pharmaceuticals, Inc

Completed

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Bladder Neoplasms

Netherlands
Spectrum Pharmaceuticals, Inc

Completed

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Spectrum Pharmaceuticals, Inc
Allergan

Terminated

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

United States, Poland, Czechia, Slovakia
Onxeo
Spectrum Pharmaceuticals, Inc

Completed

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Carcinoma of Unknown Primary

United States, Germany, France, Denmark

3

Subscribe